IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Georg Fertig, Frank Herting, Manfred Kubbies, Anja Limberg, Ulrike Reiff, Michael Weidner

Case Docket 21724

For: OXIME DERIVATIVES AND THEIR USE AS PHARMACEUTICALLY ACTIVE AGENTS

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 March 31, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1-A2, B1-B5 and C1-C5 listed on Form PTO-1449 are enclosed.

Document B1, which is not written in the English language, corresponds to U.S. Patent No. 5,137,918 (Document A1), a copy of which is attached and submitted with Document B1.

Document B4, which is not written in the English language, corresponds to U.S. Patent No. 3,810,910 (Document A2), a copy of which is attached and submitted with Document B4.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Lyman H. Smith (Reg. No. 44342) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-3916

Telefax: (973) 235-2363

140632

•	$^{\prime}$	
	∕∵	١
	`	,

Examiner

Signature

Date Considered

Substitute for form 1449A/PTO Complete if Known **Application Number** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date First Name Inventor Georg Fertig et al. (Use several sheets if necessary) Group Art Unit **Examiner Name** Sheet of 2 Attorney Docket Number 21724 U.S. PATENT DOCUMENTS U.S. Patent Document Examiner Cite Name of Patentee or Applicant of Date of Publication of Kind Code² Initials' No.1 Cited Document Cited document Number (if known) MM-DD-YYYY 5,137,918 Weiershausen et al. A1 08/11/1992 A2 3,810,910 Meyer et al. 05/14/1974 FOREIGN PATENT DOCUMENTS Foreign Patent Document $\overline{T^6}$ Date of Publication of Examiner Cite Cited Document Name of Patentee or Office³ Kind Code⁵ Number⁴ Initials' No.1 Applicant of Cited Document MM-DD-YYYY (if known) **B**1 EP 242 851 Gödecke 10/28/1987 Aktiengesellschaft Mitsui Chemicals, Inc. B2 EP 847 992 06/17/1998 DE 2 062 265 **B3** Finotto, M. 05/18/1972 $\sqrt{}$ **B4** FR 2 167 954 Bayer AG 08/24/1973 **B5** WO 03/013484 F.Hoffmann-La Roche 02/20/2003 AG

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

To be a standard of the communication of the patent of the communication of the communication

\sim
//
\sim
•

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(Use several sheets if necessary)

Of 2

2

Sheet

Complete if Known				
Application Number				
Filing Date				
First Name Inventor	Georg Fertig et al.			
Group Art Unit				
Examiner Name				
Attorney Docket Number	21724			

	NON PATENT LITERATURE DOCUMENTS			
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	T ²	
Initials'	No.1	of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published		
	C1	Koyama et al., Blood, 96, pp. 1490-1495 (2000)		
	C2	Rastogi et al., Indian J. Chem., 21B, pp. 485-487 (1982)		
	C2	Mall et al. 7. Cham. 17. m. 122 124 (1077)	V	
		Moll et al., Z. Chem., 17, pp. 132-134 (1977)	-	
	C4	Hassan et al., Indian J. Chem., 39B, pp. 764-768 (2000)		
	C5	Curtin et al., J. Med. Chem., 41, pp. 74-95 (1998)		
<u></u> -				
 .			-	
		· · · · · · · · · · · · · · · · · · ·		
Examiner		DATE		
Signature		CONSIDERED CONSIDERED CONSIDERED		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

140630